Targeting alpha synuclein aggregation and its downstream effects offers promising therapeutic avenues for neurodegenerative diseases. Strategies include the development of small molecules or antibodies that inhibit aggregation, enhance clearance, or stabilize the protein in its non-pathogenic forms. Additionally, gene therapy approaches to reduce alpha synuclein expression are being explored. The complexity of alpha synucleinâs roles in cellular physiology and pathology necessitates a nuanced approach to therapeutic intervention.
